Skip to content
Licensed Unlicensed Requires Authentication Published online by De Gruyter February 8, 2021

Computational studies on statins photoactivity

Donata Pluskota-Karwatka ORCID logo and Marcin Hoffmann
From the journal Physical Sciences Reviews

Abstract

Statins are popular drugs widely prescribed to control hypercholesterolaemia and to prevent cardiovascular diseases. Synthetic statins constitute a group of pharmaceuticals which are very sensitive to exposure to light in both UVA and UVB ranges. Light, by causing drugs degradation, can essentially change their pharmaceutical properties leading even to the loss of therapeutic activity and/or to the formation of deleterious photoproducts. Drugs which exhibit photochemical reactivity may elicit undesired adverse effects. A detailed understanding of mechanisms involved in molecular basis of these effects origin is very important for evaluating the photobiological risk associated with therapy in which drugs prone to exposure to light are involved. In this work we critically discussed finding regarding the mechanisms of synthetic statins phototransformation. We showed inconsistency of some previously reported facts and revised earlier presented studies. We also completed the lack of information on pitavastatin photobehaviour. This all together resulted in proposal of new schemes for the statins photodecomposition. We reviewed data derived from both experimental and computational methods. Studies of photochemical problems by the use of theoretical methods enable getting insight into areas of some fascinating events that experimental techniques can touch only indirectly. Besides effect of light, phenomenon of statins’ sensitivity to pH and resulting implications were discussed. Statins undergo pH-dependent interconversion between their pharmacologically active hydroxy acid and inactive lactone forms, and it was shown that for both forms, drugs’ interactions should be considered. Knowledge of the statins interconversion mechanisms is important for understanding how differences in the structures of their molecules can affect the drugs’ activity.


Corresponding author: Donata Pluskota-Karwatka, Faculty of Chemistry, Adam Mickiewicz University, Uniwersytetu Poznańskiego 8, 61-614Poznań, Poland, E-mail:

  1. Author contribution: All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission.

  2. Research funding: None declared.

  3. Conflict of interest statement: The authors declare no conflicts of interest regarding this article.

References

1. Endo, A. A historical perspective on the discovery of statins. Proc Jpn Acad Ser B Phys Biol Sci 2010;86:484–93.10.2183/pjab.86.484Search in Google Scholar

2. Schachter, M. Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update. Fundam Clin Pharmacol 2005;19:117–25. https://doi.org/10.1111/j.1472-8206.2004.00299.x.Search in Google Scholar

3. Istvan, E. Statin inhibition of HMG-CoA reductase: a 3-dimensional view. Atherosclerosis Suppl 2003;4:3–8. https://doi.org/10.1016/S1567-5688(03)00003-5.Search in Google Scholar

4. Istvan, ES, Deisenhofer, J. Structural mechanism for statin inhibition of HMG-CoA reductase. Science 2001;292:1160–4. https://doi.org/10.1126/science.1059344.Search in Google Scholar PubMed

5. Bellosta, S, Paoletti, R, Corsini, A. History and development of HMG-CoA reductase inhibitors, Schmitz, G and Torzewski, M, editors. Switzerland: Birkhauser Verlag; 2002, n.d.10.1007/978-3-0348-8135-7_1Search in Google Scholar

6. Litvić, M, Šmic, K, Vinković, V, Filipan-Litvić, M. A study of photodegradation of drug rosuvastatin calcium in solid state and solution under UV and visible light irradiation: the influence of certain dyes as efficient stabilizers. J Photochem Photobiol Chem 2013;252:84–92. https://doi.org/10.1016/j.jphotochem.2012.11.008.Search in Google Scholar

7. Cermola, F, DellaGreca, M, Iesce, MR, Montanaro, S, Previtera, L, Temussi, F, et al.. Irradiation of fluvastatin in water. J Photochem Photobiol Chem 2007;189:264–71. https://doi.org/10.1016/j.jphotochem.2007.02.011.Search in Google Scholar

8. Cermola, F, DellaGreca, M, Iesce, MR, Montanaro, S, Previtera, L, Temussi, F. Photochemical behavior of the drug atorvastatin in water. Tetrahedron 2006;62:7390–5. https://doi.org/10.1016/j.tet.2006.05.027.Search in Google Scholar

9. Grobelny, P, Viola, G, Vedaldi, D, Dall’Acqua, F, Gliszczyńska-Świgło, A, Mielcarek, J. Photostability of pitavastatin—a novel HMG-CoA reductase inhibitor. J Pharmaceut Biomed Anal 2009;50:597–601. https://doi.org/10.1016/j.jpba.2008.10.004.Search in Google Scholar PubMed

10. Sobotta, L, Kachlicki, P, Marczak, L, Kryjewski, M, Mielcarek, J. Photochemical activity of glenvastatin, a HMG-CoA reductase inhibitor. J Photochem Photobiol Chem 2011;224:1–7. https://doi.org/10.1016/j.jphotochem.2011.08.008.Search in Google Scholar

11. Nardi, G, Lhiaubet-Vallet, V, Leandro-Garcia, P, Miranda, MA. Potential phototoxicity of rosuvastatin mediated by its dihydrophenanthrene-like photoproduct. Chem Res Toxicol 2011;24:1779–85. https://doi.org/10.1021/tx200341f.Search in Google Scholar

12. Viola, G, Grobelny, P, Linardi, MA, Salvador, A, Basso, G, Mielcarek, J, et al.. The phototoxicity of fluvastatin, an HMG-CoA reductase inhibitor, is mediated by the formation of a benzocarbazole-like photoproduct. Toxicol Sci Off J Soc Toxicol 2010;118:236–50. https://doi.org/10.1093/toxsci/kfq228.Search in Google Scholar

13. Montanaro, S, Lhiaubet-Vallet, V, Iesce, M, Previtera, L, Miranda, MA. A mechanistic study on the phototoxicity of atorvastatin: singlet oxygen generation by a phenanthrene-like photoproduct. Chem Res Toxicol 2009;22:173–8. https://doi.org/10.1021/tx800294z.Search in Google Scholar

14. Jemal, M, Ouyang, Z, Powell, ML. Direct-injection LC-MS-MS method for high-throughput simultaneous quantitation of simvastatin and simvastatin acid in human plasma. J Pharmaceut Biomed Anal 2000;23:323–40.10.1016/S0731-7085(00)00309-5Search in Google Scholar

15. Zhao, JJ, Xie, IH, Yang, AY, Roadcap, BA, Rogers, JD. Quantitation of simvastatin and its beta-hydroxy acid in human plasma by liquid-liquid cartridge extraction and liquid chromatography/tandem mass spectrometry. J Mass Spectrom 2000;35:1133–43.10.1002/1096-9888(200009)35:9<1133::AID-JMS42>3.0.CO;2-XSearch in Google Scholar

16. Sakaeda, T, Fujino, H, Komoto, C, Kakumoto, M, Jin, J, Iwaki, K, et al.. Effects of acid and lactone forms of eight HMG-CoA reductase inhibitors on CYP-mediated metabolism and MDR1-mediated transport. Pharm Res 2006;23:506–12. https://doi.org/10.1007/s11095-005-9371-5.Search in Google Scholar

17. Fujino, H, Saito, T, Tsunenari, Y, Kojima, J, Sakaeda, T. Metabolic properties of the acid and lactone forms of HMG-CoA reductase inhibitors. Xenobiotica Fate Foreign Compd Boil Syst 2004;34:961–71. https://doi.org/10.1080/00498250400015319.Search in Google Scholar

18. Astarita, A, DellaGreca, M, Iesce, MR, Montanaro, S, Previtera, L, Temussi, F. Polycyclic compounds by sunlight exposure of the drug rosuvastatin in water. J Photochem Photobiol Chem 2007;187:263–8. https://doi.org/10.1016/j.jphotochem.2006.10.007.Search in Google Scholar

19. Sajimon, MC, Lewis, FD. Photocyclization of a conformationally constrained 2-vinylbiphenyl. Photochem Photobiol Sci 2005;4:789–91. https://doi.org/10.1039/b511270b.Search in Google Scholar

20. Lewis, FD, Sajimon, MC, Zuo, X, Rubin, M, Gevorgyan, V. Competitive 1,2- and 1,5-hydrogen shifts following 2-vinylbiphenyl photocyclization. J Org Chem 2005;70:10447–52. https://doi.org/10.1021/jo051730y.Search in Google Scholar

21. Jarmużek, D, Pedzinski, T, Hoffmann, M, Siodła, T, Pluskota-Karwatka, D. Phototransformations of pitavastatin - the inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase. J Photochem Photobiol Chem 2020;389:112243. https://doi.org/10.1016/j.jphotochem.2019.112243.Search in Google Scholar

22. Liu, Y, Wang, Q-L, Chen, Z, Zhou, C-S, Xiong, B-Q, Zhang, P-L, et al.. Oxidative radical ring-opening/cyclization of cyclopropane derivatives. Beilstein J Org Chem 2019;15:256–78. https://doi.org/10.3762/bjoc.15.23.Search in Google Scholar PubMed PubMed Central

23. Mielcarek, J, Kula, M, Zych, R, Grobelny, P. Kinetic studies on fluvastatin photodegradation in solutions. React Kinet Catal Lett 2005;86:119–26. https://doi.org/10.1007/s11144-005-0302-6.Search in Google Scholar

24. Mielcarek, J, Grobelny, P, Osmałek, T. Identification of photoproducts of fluvastatin in solutions. J Planar Chromatogr 2009;22:137–40. https://doi.org/10.1556/JPC.22.2009.2.11.Search in Google Scholar

25. Jarmużek, D, Pedzinski, T, Hoffmann, M, Siodła, T, Salus, K, Pluskota-Karwatka, D. Experimental and theoretical studies on fluvastatin primary photoproduct formation. Phys Chem Chem Phys 2017;19:21946–54. https://doi.org/10.1039/C7CP01094J.Search in Google Scholar

26. Pluskota-Karwatka, D, Hoffmann, M. Transformations of statins: effect of light and pH. Curr Org Chem 2018;22:1926–39. https://doi.org/10.2174/1385272822666180913112356.Search in Google Scholar

27. Lednev, IK, Mathivanan, N, Johnston, LJ. Photochemistry of stilbene adsorbed on silica gel and NaX zeolite. A diffuse reflectance laser flash photolysis study. J Phys Chem 1994;98:11444–51. https://doi.org/10.1021/j100095a030.Search in Google Scholar

28. Barik, R, Bhattacharyya, K, Das, PK, George, MV. Photochemical transformations of 1-imidazolyl-1,2-dibenzoylalkenes. Steady-state and laser flash photolysis investigations. J Org Chem 1986;51:3420–8. https://doi.org/10.1021/jo00368a003.Search in Google Scholar

29. Alarcón, E, González-Béjar, M, Gorelsky, S, Ebensperger, R, Lopez-Alarcón, C, Netto-Ferreira, JC, et al.. Photophysical characterization of atorvastatin (Lipitor®) ortho-hydroxy metabolite: role of hydroxyl group on the drug photochemistry. Photochem Photobiol Sci 2010;9:1378–84. https://doi.org/10.1039/C0PP00102C.Search in Google Scholar PubMed

30. Ando, H, Tsuruoka, S, Yanagihara, H, Sugimoto, K, Miyata, M, Yamazoe, Y, et al.. Effects of grapefruit juice on the pharmacokinetics of pitavastatin and atorvastatin. Br J Clin Pharmacol 2005;60:494–7. https://doi.org/10.1111/j.1365-2125.2005.02462.x.Search in Google Scholar PubMed PubMed Central

31. Hoffmann, M, Nowosielski, M. DFT study on hydroxy acid–lactone interconversion of statins: the case of atorvastatin. Org Biomol Chem 2008;6:3527–31. https://doi.org/10.1039/B803342K.Search in Google Scholar

32. Kearney, AS, Crawford, LF, Mehta, SC, Radebaugh, GW. The interconversion kinetics, equilibrium, and solubilities of the lactone and hydroxyacid forms of the HMG-CoA reductase inhibitor, CI-981. Pharm Res 1993;10:1461–5.10.1023/A:1018923325359Search in Google Scholar

33. Kaufman, MJ. Rate and equilibrium constants for acid-catalyzed lactone hydrolysis of HMG-CoA reductase inhibitors. Int J Pharm 1990;66:97–106. https://doi.org/10.1016/0378-5173(90)90389-L.Search in Google Scholar

34. Grabarkiewicz, T, Grobelny, P, Hoffmann, M, Mielcarek, J. DFT study on hydroxy acid–lactone interconversion of statins: the case of fluvastatin. Org Biomol Chem 2006;4:4299–306. https://doi.org/10.1039/B612999B.Search in Google Scholar PubMed

35. Nissen, SE, Tuzcu, EM, Schoenhagen, P, Crowe, T, Sasiela, WJ, Tsai, J, et al.. Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. N Engl J Med 2005;352:29–38. https://doi.org/10.1056/NEJMoa042000.Search in Google Scholar PubMed

36. Mills, EJ, Rachlis, B, Wu, P, Devereaux, PJ, Arora, P, Perri, D. Primary prevention of cardiovascular mortality and events with statin treatments: a network meta-analysis involving more than 65,000 patients. J Am Coll Cardiol 2008;52:1769–81. https://doi.org/10.1016/j.jacc.2008.08.039.Search in Google Scholar PubMed

37. Hiro, T, Kimura, T, Morimoto, T, Miyauchi, K, Nakagawa, Y, Yamagishi, M, et al.. Effect of intensive statin therapy on regression of coronary atherosclerosis in patients with acute coronary syndrome: a multicenter randomized trial evaluated by volumetric intravascular ultrasound using pitavastatin versus atorvastatin (JAPAN-ACS [Japan assessment of pitavastatin and atorvastatin in acute coronary syndrome] study). J Am Coll Cardiol 2009;54:293–302. https://doi.org/10.1016/j.jacc.2009.04.033.Search in Google Scholar PubMed

38. Quiec, D, Mazière, C, Auclair, M, Santus, R, Gardette, J, Redziniak, G, et al.. Lovastatin enhances the photocytotoxicity of UVA radiation towards cultured N.C.T.C. 2544 human keratinocytes: prevention by cholesterol supplementation and by a cathepsin inhibitor. Biochem J 1995;310:305–9. https://doi.org/10.1042/bj3100305.Search in Google Scholar PubMed PubMed Central

39. Sparks, DL, Kryscio, RJ, Sabbagh, MN, Connor, DJ, Sparks, LM, Liebsack, C. Reduced risk of incident AD with elective statin use in a clinical trial cohort. Curr Alzheimer Res 2008;5:416–21.10.2174/156720508785132316Search in Google Scholar PubMed

40. Eckert, GP, Wood, WG, Müller, WE. Statins: drugs for Alzheimer’s disease? J Neural Transm 1996;112:1057–71. https://doi.org/10.1007/s00702-004-0273-1.Search in Google Scholar PubMed

41. Ajith, TA, Riji, T, Anu, V. In vitro anti-oxidant and DNA protective effects of the novel 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor rosuvastatin. Clin Exp Pharmacol Physiol 2008;35:625–9. https://doi.org/10.1111/j.1440-1681.2007.04853.x.Search in Google Scholar PubMed

42. Demierre, M-F, Higgins, PDR, Gruber, SB, Hawk, E, Lippman, SM. Statins and cancer prevention. Nat Rev Cancer 2005;5:930–42. https://doi.org/10.1038/nrc1751.Search in Google Scholar PubMed

43. Chan, KKW, Oza, AM, Siu, LL. The statins as anticancer agents. Clin Cancer Res Off J Am Assoc Cancer Res 2003;9:10–9.Search in Google Scholar

44. Staedler, D, Chapuis-Bernasconi, C, Dehmlow, H, Fischer, H, Juillerat-Jeanneret, L, Aebi, JD. Cytotoxic effects of combination of oxidosqualene cyclase inhibitors with atorvastatin in human cancer cells. J Med Chem 2012;55:4990–5002. https://doi.org/10.1021/jm300256z.Search in Google Scholar PubMed

Published Online: 2021-02-08

© 2020 Walter de Gruyter GmbH, Berlin/Boston